A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies (innovaTV 206)

Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies

Study Overview

• Status: Completed
• Conditions: Solid Tumor
• Intervention / Treatment: Drug: tisotumab vedotin

Detailed Description

Part 1 of this trial will determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) and the safety profile of tisotumab vedotin in subjects with solid malignancies. Part 2 of this trial will enroll subjects with cervical cancer to provide further data on the safety, tolerability, PK and anti-tumor activity

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Japan
  • Chiba-Ken
    • Kashiwa-shi, Chiba-Ken, Japan, 277-8577
      • National Cancer Center Hosptial East
  • Ehime-Ken
    • Matsuyama-Shi, Ehime-Ken, Japan, 791-0280
      • NHO Shikoku Cancer Center
  • Hokkaido
    • Sapporo-shi, Hokkaido, Japan, 003-0804
      • Nho Hokkaido Cancer Center
  • Kanagawa-Ken
    • Yokohama-shi, Kanagawa-Ken, Japan, 241-8515
      • Kanagawa cancer center
  • Saitama-Ken
    • Hidaka-shi, Saitama-Ken, Japan, 350-1298
      • Saitama Medical University International Medical Center
  • Shizuoka-Ken
    • Sunto-gun, Shizuoka-Ken, Japan, 411-8777
      • Shizuoka Cancer Center
  • Tokyo-To
    • Chuo-ku, Tokyo-To, Japan, 104-0045
      • National Cancer Center Hospital
    • Shinjuku-ku, Tokyo-To, Japan, 160-8582
      • Keio University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria (Main):

• PART 1 ONLY: Subjects with locally advanced or metastatic solid tumors, who have experienced disease progression while on standard therapy or are intolerant of, or not eligible for, standard therapy.
• PART 2 ONLY: Subjects with extra-pelvic metastatic or recurrent cervical cancer including squamous cell, adenocarcinoma or adenosquamous histology who have experienced disease progressed on standard of care chemotherapy in combination with bevacizumab, if eligible.

Patients must not have received more than 2 prior systemic treatment regimens for recurrent or metastatic cervical disease.

• Measurable disease according to RECIST v1.1
• Must be at least 20 years of age on the day of signing informed consent
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Is not pregnant, breastfeeding, or expecting to conceive children within the projected duration of the trial and for at least 6 months after the last trial treatment administration
• Women of childbearing potential must agree to use adequate contraception during and for 6 months after the last dose of trial treatment administration
• A man who is sexually active with a WOCBP and has not had a vasectomy must agree to use a barrier method of birth control (Part 1 only)
• Must provide signed informed consent before any trial-related activity is carried out.

Exclusion Criteria (Main):

• PART 2 ONLY: Clinically relevant bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.
• Known past or current coagulation defects leading to an increased risk of bleeding.
• Ongoing major bleeding.
• Has an active ocular surface disease at baseline. Subjects with prior history of cicatricial conjunctivitis are ineligible

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Experimental tisotumab vedotin; Open label, single arm trial where tisotumab vedotin will be administered	Drug: tisotumab vedotin; Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose Escalation and Dose Expansion: Incidence of drug-related Adverse Events (AEs) and Serious Adverse Events (SAEs) by CTCAE v5.0 [Safety]		Throughout the trial - until 90 days after last dose of tisotumab vedotin
Dose Escalation and Dose Expansion: Incidence of Dose Limiting Toxicities (DLTs), AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities [Tolerability]		Throughout the trial - until 90 days after last dose of tisotumab vedotin
Dose Escalation: maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of tisotumab vedotin		Up to 21 days after the first dose of tisotumab vedotin (each cycle is 21 days)
Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Maximum concentration (Cmax) after dosing		Up to approximately 42 days after initial dose of tisotumab vedotin
Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC(0-t))		Up to approximately 42 days after initial dose of tisotumab vedotin
Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin : Rate at which the drug is removed from the body (CL)		Up to approximately 42 days after initial dose of tisotumab vedotin
Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Elimination half-life of the drug (T½)		Up to approximately 42 days after initial dose of tisotumab vedotin
Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Time after dosing at which the maximum drug concentration was observed (Tmax)		Up to approximately 42 days after initial dose of tisotumab vedotin
Dose Escalation and Dose Expansion: Assess immunogenicity of tisotumab vedotin by measuring and assessing Anti-drug Antibody (ADA)	Summarized by descriptive statistics by trial part and dose	Throughout and at the end of trial (up to 90 days after last dose of tisotumab vedotin)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose Escalation and Dose Expansion: Evaluate antitumor activity of tisotumab vedotin by assessing Objective Response Rate (ORR) (based on RECIST 1.1)	ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR)	Up to approximately 6 months after the first dose of tisotumab vedotin
Dose Escalation and Dose Expansion: Evaluate antitumor activity of tisotumab vedotin by assessing Duration of Response (DOR) (based on RECIST 1.1)	The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.	Up to approximately 6 months after the first dose of tisotumab vedotin
Dose Escalation and Dose Expansion: Evaluate antitumor activity of tisotumab vedotin by assessing Time to Response (TTR) (based on RECIST 1.1)	TTR for a responder is defined as the time from the start of treatment with study drug to the first objective tumor response observed.	Up to approximately 6 months after the first dose of tisotumab vedotin

Collaborators and Investigators

• Sponsor: Genmab
• Collaborators: Seagen Inc.
• Investigators: Principal Investigator: Keiichi Fujiwara, Professor, Saitama Medical University International Medical Center

Publications and helpful links

General Publications

• Yonemori K, Kuboki Y, Hasegawa K, Iwata T, Kato H, Takehara K, Hirashima Y, Kato H, Passey C, Buchbjerg JK, Harris JR, Andreassen CM, Nicacio L, Soumaoro I, Fujiwara K. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study. Cancer Sci. 2022 Aug;113(8):2788-2797. doi: 10.1111/cas.15443. Epub 2022 Jun 15.

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 27, 2019
• Primary Completion (ACTUAL): August 14, 2020
• Study Completion (ACTUAL): October 30, 2021

Study Registration Dates

• First Submitted: March 29, 2019
• First Submitted That Met QC Criteria: April 11, 2019
• First Posted (ACTUAL): April 12, 2019

Study Record Updates

• Last Update Posted (ACTUAL): June 23, 2022
• Last Update Submitted That Met QC Criteria: June 17, 2022
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: cervical cancer; tisotumab vedotin
• Additional Relevant MeSH Terms: Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Tisotumab vedotin
• Other Study ID Numbers: GCT1015-06; JapicCTI-194639 (REGISTRY: JAPIC)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No